ATHA [NASD]
Athira Pharma, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own0.70% Shs Outstand37.59M Perf Week-66.98%
Market Cap105.38M Forward P/E- EPS next Y-3.24 Insider Trans-4.34% Shs Float35.77M Perf Month-68.47%
Income-67.00M PEG- EPS next Q-0.64 Inst Own75.40% Short Float8.22% Perf Quarter-78.36%
Sales- P/S- EPS this Y-141.90% Inst Trans7.08% Short Ratio3.71 Perf Half Y-77.93%
Book/sh8.03 P/B0.35 EPS next Y-26.50% ROA-19.80% Target Price11.00 Perf Year-73.80%
Cash/sh6.98 P/C0.40 EPS next 5Y- ROE-20.40% 52W Range2.53 - 16.65 Perf YTD-78.59%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-83.24% Beta-
Dividend %- Quick Ratio28.40 Sales past 5Y- Gross Margin- 52W Low10.28% ATR0.76
Employees34 Current Ratio28.40 Sales Q/Q- Oper. Margin- RSI (14)16.92 Volatility11.71% 7.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-125.20% Profit Margin- Rel Volume2.52 Prev Close2.85
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume793.03K Price2.79
Recom1.70 SMA20-62.84% SMA50-68.73% SMA200-74.30% Volume1,950,693 Change-2.11%
Jun-23-22Downgrade Stifel Buy → Hold $36 → $5
Jun-23-22Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-23-22Downgrade Jefferies Buy → Hold $32 → $3
May-10-22Initiated BTIG Research Buy $33
Apr-21-22Initiated Berenberg Buy $33
Dec-15-21Initiated Goldman Neutral $16
Oct-13-20Initiated Stifel Buy $36
Oct-13-20Initiated JMP Securities Mkt Outperform $51
Oct-13-20Initiated Jefferies Buy $30
Oct-13-20Initiated Goldman Buy $53
Jun-22-22 04:49PM  
01:29PM  
11:31AM  
08:25AM  
08:21AM  
07:00AM  
Jun-07-22 07:00AM  
May-22-22 10:43AM  
May-19-22 12:06PM  
May-17-22 05:39AM  
May-16-22 04:49PM  
07:00AM  
May-12-22 04:05PM  
May-11-22 04:15PM  
May-09-22 07:00AM  
May-05-22 12:04PM  
08:00AM  
May-04-22 06:46PM  
Apr-28-22 12:54AM  
Apr-26-22 08:00AM  
Apr-20-22 09:02AM  
Apr-12-22 12:45AM  
Apr-05-22 04:04PM  
Apr-04-22 07:00AM  
Mar-31-22 04:26PM  
Mar-30-22 12:12PM  
09:51AM  
09:40AM  
07:30AM  
Mar-24-22 04:05PM  
Mar-21-22 07:05AM  
07:00AM  
Mar-20-22 04:50AM  
Mar-18-22 02:39PM  
Mar-17-22 07:00AM  
Mar-14-22 07:00AM  
Mar-02-22 02:15PM  
Feb-22-22 07:05AM  
07:00AM  
Feb-07-22 06:38PM  
Jan-31-22 05:52PM  
07:00AM  
Jan-25-22 07:00AM  
Jan-05-22 07:00AM  
Dec-13-21 09:47AM  
04:41AM  
Nov-10-21 04:05PM  
11:50AM  
Nov-08-21 07:00AM  
Oct-29-21 07:00AM  
Oct-25-21 01:38AM  
Oct-23-21 02:18PM  
Oct-22-21 05:00PM  
12:31PM  
11:45AM  
08:22AM  
07:36AM  
Oct-21-21 05:11PM  
04:05PM  
Sep-29-21 08:05AM  
Sep-20-21 05:57PM  
Sep-17-21 05:50PM  
Sep-14-21 06:43AM  
Aug-25-21 06:17PM  
Aug-24-21 07:45PM  
03:33PM  
11:00AM  
10:18AM  
09:37AM  
01:10AM  
Aug-23-21 11:26PM  
07:45PM  
07:03PM  
02:43PM  
02:20PM  
12:30PM  
12:00PM  
11:30AM  
11:00AM  
11:00AM  
09:11AM  
09:10AM  
07:30AM  
06:34AM  
02:02AM  
Aug-22-21 06:30PM  
08:27AM  
08:27AM  
Aug-21-21 01:57PM  
11:51AM  
09:03AM  
Aug-20-21 10:50PM  
07:10PM  
06:24PM  
04:57PM  
03:00PM  
02:14PM  
01:12PM  
11:45AM  
11:00AM  
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Worthington MarkGeneral CounselJun 23Sale2.692,6147,03219,097Jun 24 07:55 PM
MILESON GLENNAChief Financial OfficerJun 23Sale2.692,6147,032109,167Jun 24 07:53 PM
Litton Mark JamesChief Executive OfficerJun 23Sale2.697,96021,412128,555Jun 24 07:51 PM
Lenington RachelChief Operating OfficerJun 23Sale2.694,19311,2795,807Jun 24 07:50 PM
CHURCH KEVINExecutive VP, ResearchJun 23Sale2.692,6147,03257,695Jun 24 07:25 PM
CHURCH KEVINExecutive VP, ResearchJun 08Option Exercise1.352,5003,37550,309Jun 10 05:53 PM
MILESON GLENNAChief Financial OfficerApr 11Option Exercise10.643,00031,920100,060Apr 12 07:36 PM
Romano Kelly ADirectorMar 31Buy13.118,000104,8808,315Apr 01 04:40 PM
CHURCH KEVINExecutive VP, ResearchFeb 18Option Exercise1.193,1523,75147,566Feb 18 07:38 PM
MILESON GLENNAChief Financial OfficerJan 04Option Exercise1.356,3058,51297,060Jan 06 05:08 PM
Litton Mark JamesChief Operating OfficerAug 17Option Exercise1.3550,44068,094114,873Aug 19 05:05 PM
MOEBIUS HANSChief Medical OfficerJul 21Option Exercise1.3528,37238,30230,427Jul 21 04:47 PM